INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference Boca Raton

INmune Bio to Present Phase 2 MINDFuL

Trial Findings of XPro at the Alzheimer's Association International Conference

Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio

Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro , a novel selective

soluble TNF inhibitor, will be released in an oral presentation at the Alzheimer's Association International Conference (AAIC) in

Toronto, Canada. The presentation, to be given by Dr. Sharon Cohen, is scheduled in a Developing Topics session on Tuesday, July 29, 2025,

between 2:00 and 3:30 PM ET in room 718.

The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study

examining the potential of XPro to slow cognitive decline in early-stage Alzheimer's disease (AD) by targeting neuroinflammation.

The trial enrolled 208 participants with early AD who had one or more biomarkers of inflammation - elevated C-reactive protein

(CRP), erythrocyte sedimentation rate (ESR), hemoglobin A1c (HbA1c), or an ApoE4 allele. Participants received XPro or placebo

in a 2:1 ratio, respectively, for 24 weeks, with changes in cognition measured via the Early Mild Alzheimer's Cognitive Composite

While the primary endpoint was not met in the overall modified-intent-to-treat

mITT group, key changes in clinical measures of cognition, behavior, and AD-related biomarkers demonstrated a consistent benefit of treatment

with XProTM after 6 months in a subpopulation of patients with biomarker confirmed amyloid-beta (A ) pathology and

2 of the blood biomarkers of systemic inflammation.

"We are encouraged by the promising findings of the MINDFuL trial,

which highlight the potential of XPro to address neuroinflammation in Alzheimer's disease," said Dr. CJ Barnum, Vice

President of CNS Drug Development at INmune Bio. "These meaningful results reinforce our commitment to developing this therapy that

could significantly impact patients and their families."

Neurologist Dr. Sharon Cohen, site principal investigator of the MINDFuL

trial and medical director of the Toronto Memory Program, will deliver the conference presentation. "I'm pleased to

share more of this eagerly anticipated data with the Alzheimer's community," stated Dr. Cohen. "Targeting inflammation

through XPro offers a novel and exciting therapeutic approach that could enhance outcomes for individuals with Alzheimer's,

whether used alone or in combination with other treatments."

INmune Bio anticipates submitting a publication by mid-August of the

MINDFuL Phase 2 study results. Additionally, the company is seeking a strategic partnership to accelerate the further development

of XPro as a treatment for Alzheimer's disease.

INmune Bio wishes to extend their gratitude to the MINDFuL participants,

caregivers, site staff, vendors, and any others who supported the efforts of this proof-of-concept Phase 2 clinical trial.

About MINDFuL (NCT05318976)

The MINDFuL trial was an international, blinded, randomized Phase 2

trial in participants with Early AD with biomarkers of elevated neuroinflammation. Early AD includes patients with MCI (mild cognitive

impairment) and mild AD. Participants were required to have at least one of four biomarkers of inflammation - elevated CRP, HbA1c,

ESR or at least one APOE 4 allele. Participants received either XPro or placebo (2:1 ratio) for 6 months by subcutaneous

injection given once per week. The cognitive endpoint was change from baseline on the EMACC composite. For more information on the MINDFuL

clinical trial, please visit www.clinicaltrials.gov or www.inmunebio.com

XPro is an advanced tumor necrosis factor (TNF) inhibitor that

targets soluble TNF (sTNF) while preserving trans-membrane TNF (tmTNF) and TNF receptors. By reducing neuroinflammation, XPro may

offer significant benefits for patients with neurologic disorders, potentially enhancing cognitive function and supporting neuronal communication.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage

biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product

platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively

neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates

are in clinical trials to determine if they can treat Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant

depression (XPro ). The Natural Killer Cell Priming Platform includes INKmune developed to prime a patient's NK cells

to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate

cancer. The third program, CORDStrom , is a proprietary allogeneic, pooled, human umbilical cord-derived mesenchymal Stromal/Stem

cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio's

product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that

any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization

of product candidates and other business and financial matters, including without limitation, trial results and data, including the results

of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro , and the prospects

for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements

as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based

on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances

may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom ,

XPro1595 (XPro , pegipanermin), and INKmune have either finished clinical trials, are still in clinical

trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory

body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will

be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited

to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial

additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product

commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans

and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities

and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q

and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect

any event or circumstance that may arise after the date of this release.

Chief Financial Officer

Head of Investor Relations